Abstract
Bleomycin pulmonary toxicity (BPT) is a well-described complication of bleomycin-containing regimens. Previous data on risk factors and the impact of BPT on survival in Hodgkin lymphoma (HL) were conflicting. We reviewed 253 HL patients treated with adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) at the Princess Margaret Hospital from 1999 to 2009 to examine the incidence and risk factors for BPT, and the effect of BPT on survival. BPT was defined by pulmonary symptoms, bilateral interstitial infiltrates on computed tomography, and the absence of infection. Kaplan-Meier estimates were used to compare overall survival (OS) and progression-free survival (PFS) between groups. The incidence of BPT was low (11%). Age ≥45 (OR = 2.5) and granulocyte colony-stimulating factor use (OR = 3.6) were identified as predictors of BPT on multivariable logistic models. At a follow-up of 5 years, OS and PFS were 88% and 82%, respectively. Neither BPT nor bleomycin discontinuation had significant impact on survival outcomes.
References
Nov 19, 1992·The New England Journal of Medicine·G P CanellosB A Peterson
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S SenanS B Kaye
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J McKeageP J Dady
Jan 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SantoroF Crippa
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Feb 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J HorningR A Olshen
Oct 16, 1993·Lancet·J H Matthews
Nov 20, 1998·The New England Journal of Medicine·D Hasenclever, V Diehl
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Aug 15, 2001·Chest·S Sleijfer
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M O'SullivanA Horwich
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B DugganBruce A Peterson
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George P CanellosDonna Niedzwiecki
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G MartinStephen M Ansell
Apr 27, 2007·British Journal of Haematology·Andrew M EvensLeo I Gordon
Oct 11, 2008·Annals of Hematology·Dominic FongAlexandar Tzankov
Aug 3, 2010·Annals of Hematology·Joanne NgeowSoon Thye Lim
Jul 12, 2011·Leukemia & Lymphoma·Leonard A MinukJoy E Mangel
Sep 16, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Richard T HoppeUNKNOWN NCCN Hodgkin Lymphoma
Nov 26, 2011·Blood·Andrew M EvensSonali M Smith
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Feb 3, 2016·Blood·Boris BöllPeter Borchmann
Jun 23, 2016·The New England Journal of Medicine·Peter JohnsonSally Barrington
Citations
Apr 28, 2018·Medical Oncology·Yuki MaruyamaYasutomo Nasu
Jul 24, 2018·Clinical Journal of Oncology Nursing·Sarah Merkle, Susan S Tavernier
Sep 14, 2019·Leukemia & Lymphoma·Kekoa TaparraStephen M Ansell
Apr 23, 2020·Personalized Medicine·Dimpal N ThakkarBiswajit Dubashi
Jan 20, 2020·International Journal of Hematology·Satoshi IchikawaHideo Harigae
Sep 19, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Graça M DoresLindsay M Morton
Nov 1, 2020·Clinical Lymphoma, Myeloma & Leukemia·Ryujiro HaraKiyoshi Ando
Jul 1, 2019·Respiratory Medicine·Leyla Pur OzyigitGunnur Deniz